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Parkinson’s disease (PD) is a common neurodegen-
erative disorder. Functional interactions between
some PD genes, like PINK1 and parkin, have been
identified, but whether other ones interact remains
elusive. Here we report an unexpected genetic inter-
action between two PD genes, VPS35 and EIF4G1.
We provide evidence that EIF4G1 upregulation
causes defects associated with protein misfolding.
Expression of a sortilin protein rescues these de-
fects, downstream of VPS35, suggesting a potential
role for sortilins in PD. We also show interactions
between VPS35, EIF4G1, and a-synuclein, a protein
with a key role in PD. We extend our findings from
yeast to an animal model and show that these
interactions are conserved in neurons and in trans-
genic mice. Our studies reveal unexpected genetic
and functional interactions between two seemingly
unrelated PD genes and functionally connect them
to a-synuclein pathobiology in yeast, worms, and
mouse. Finally, we provide a resource of candidate
PD genes for future interrogation.
INTRODUCTION
Parkinson’s disease (PD) is a debilitating neurodegenerative dis-
order that affects more than 2% of adults over 60 (Jankovic,
2008; Massano and Bhatia, 2012). It is mostly a sporadic dis-
ease, but the rare genetic forms have provided key insight into
disease mechanisms that are also relevant to sporadic PD.
With the emergence of next-generation sequencing strategies,
together with traditional genetic linkage approaches, and
genome-wide association studies (GWASs), risk genes associ-
ated with PD are being rapidly discovered (Do et al., 2011;
Hamza et al., 2010; Nalls et al., 2011, 2014a; International Parkin-76 Neuron 85, 76–87, January 7, 2015 ª2015 Elsevier Inc.son’s Disease Genomics Consortium, 2011; Li et al., 2013; Lill
et al., 2012; Satake et al., 2009; Simo´n-Sa´nchez et al., 2009;
Trinh and Farrer, 2013;Wan et al., 2014) and are beginning to illu-
minate cellular pathways and functions as critical to disease
pathogenesis (Nalls et al., 2014b; Trinh and Farrer, 2013). As
the list of PD disease genes grows, it will be important to define
whether these genes interact with one another or whether they
function independently. Indeed, compelling evidence points to
genetic interactions between some PD genes (e.g., parkin and
PINK1 [Clark et al., 2006; Park et al., 2006], ATP13A2 and a-syn-
uclein [Gitler et al., 2009], LRRK2 and parkin [Smith et al., 2005],
and glucocerebrosidase and a-synuclein [Mazzulli et al., 2011]).
Being able to group some PD genes into related functional
networks will facilitate the development of more effective
pathway-based targeted therapeutic interventions.
Many of the fundamental cellular pathologies associated with
PD, including mitochondrial dysfunction (Wan et al., 2014) and
vesicle-trafficking defects (Miklavc et al., 2014), involve impair-
ments in highly conserved cellular pathways. Therefore, simple
model organisms have emerged as powerful experimental sys-
tems for studying the basic biology underpinning even compli-
cated human neurodegenerative diseases like PD. One simple,
yet surprisingly effective, model system has been the budding
yeast Saccharomyces cerevisiae. Yeast models engineered
to express exogenous human PD risk genes (e.g., a-synuclein
or LRRK2) recapitulate key cellular phenotypes (Outeiro and
Lindquist, 2003; Xiong et al., 2010) and have been used to
perform unbiased genetic and chemical screens for phenotypic
modifiers.
Two PD genes, conserved from yeast to human, are EIF4G1
and VPS35. Mutations in EIF4G1 and VPS35were recently iden-
tified in familial PD (Chartier-Harlin et al., 2011; Vilarin˜o-Gu¨ell
et al., 2011). EIF4G1 is a large scaffold protein that functions
in translation initiation factor complex assembly (Villa et al.,
2013). VPS35 is a component of the retromer complex, which
functions to sort cellular cargo within the endocytic system. Car-
gos retained on endosomes are delivered to the vacuole (lyso-
somes in mammalian cells) for degradation. Retromer functions
to orchestrate the retrieval of some of these proteins from
endosomes back to the trans-Golgi network (TGN) (Harrison
et al., 2014). The exact mechanisms by which these genes
contribute to PD are not fully understood. Moreover, EIF4G1 is
still somewhat controversial as a bona fide PD gene. Since the
initial identification of EIF4G1 mutations in PD, there have been
several negative results (Blanckenberg et al., 2014; Lesage
et al., 2012; Nishioka et al., 2014; Siitonen et al., 2013; Sudha-
man et al., 2013) and some suggestions that the original pub-
lished mutation is found in controls and therefore it might be a
rare but benign polymorphism (Tucci et al., 2012). Therefore,
additional functional insight into potential interactions with other
PD genes and disease-relevant pathways could be informative.
The yeast VPS35 homolog is also called VPS35 and EIF4G1
has two yeast homologs, TIF4631 and TIF4632. Since TIF4631
is more closely related to human EIF4G1 and deletion of
TIF4631, but not TIF4632, causes global alterations in translation
initiation rates (Clarkson et al., 2010), we focused on TIF4631.
We performed two separate genetic screens with vps35D and
tif4631D yeast strains. We discovered a powerful genetic and
functional interaction between VPS35 and EIF4G1, which we
extend from yeast to an animal model. We define themechanism
by which these genes interact and connect VPS35 to another PD
protein, a-synuclein (a-syn). We show that VPS35 is able to
protect against a-syn-induced neurodegeneration in a mouse
model. Together, these results reveal robust genetic and func-
tional interactions between two known PD genes and illuminate
new connections to a-syn pathobiology.
RESULTS
We used synthetic genetic array (SGA) (Tong and Boone, 2006)
to introduce either the VPS35 or the TIF4631 deletion, bymating,
to a collection of 4,900 yeast strains harboring single dele-
tions in nonessential genes (Figure S1A available online). After
performing the vps35D and tif4631D synthetic lethal screens
independently (each screen replicated three times), we scored
each of the double deletions for growth. We identified 144 genes
synthetic sick or lethal with tif4631D and 59 synthetic sick or le-
thal with vps35D. (Figures S1B and S1C and Table S1). We used
GOTermFinder to identify significant gene ontology (GO) terms
enriched as hits in each screen (Boyle et al., 2004). The major
functional categories for the vps35D screen were protein target-
ing (p = 1.99 3 105) and vacuolar transport (p = 2.56 3 105).
Since Vps35 has established roles in protein transport, these
functional categories were expected and serve as proof of prin-
ciple that the screen was effective. For the tif4631D screen, the
major categories of genes enriched include transcription and
translation (p = 6.40 3 105). These too were expected, based
on the known functions of this translation initiation factor. How-
ever, we found a surprising overlap in functional categories
between both screens (Figure S1B). Enriched categories of
deletions unexpected for the tif4631D screen included genes
involved in endosomal transport (p = 1.6 3 104) and protein
targeting (p = 7.44 3 105) (Figure S1B).
In addition to similar categories of hits, we also identified 14
synthetic lethal interactions that were common to both vps35D
and tif4631D screens (Figure S1C; p < 0.0031). Among these
common interactors, the most prevalent categories enrichedwere genes involved in protein localization (p = 3 3 104) and
protein transport (p = 6 3 104). One hit common to both
screens, GCS1, is a yeast ortholog of ARFGAP1, a gene encod-
ing a GTPase-activating protein known to physically and genet-
ically interact with the PD gene LRRK2 (Xiong et al., 2010).
Remarkably, one of the strongest hits from the tif4631D screen,
INP53, is the yeast homolog of SYNJ1 in humans. Mutations in
SYNJ1 were recently identified as a cause of early-onset parkin-
sonism (Krebs et al., 2013; Quadri et al., 2013). We suggest that
future PD sequencing projects might benefit from using the addi-
tional hits from these screens as candidates to predict new PD
risk genes (Table S1).
Even though both screens enriched overlapping categories of
hits (Figure S1B), we did not identify a synthetic lethal interaction
between tif4631D and vps35D. This prompted us to consider
other types of potential genetic interactions between the two
genes—we performed a series of experiments upregulating
one gene while deleting the other and vice versa. This led us to
discover a surprising and remarkably potent interaction. Upregu-
lation of TIF4631 in wild-type (WT) yeast cells had no effect on
growth; however, it was highly toxic in vps35D cells (Figure 1A).
Upregulation of human EIF4G1 had the same effect (Figure 1B),
indicating that this function is conserved from the yeast to human
protein. Likewise, coexpression of either yeast or human VPS35
could rescue the phenotype (Figure 1B), providing further
evidence for the robust and highly conserved nature of the func-
tional interaction between VPS35 and EIF4G1. To test the spec-
ificity of the TIF4631-VPS35 genetic interaction even further, we
performed an unbiased genome-wide screen in yeast where we
overexpressed 5,500 yeast genes in the vps35D yeast cells,
looking for genes that caused toxicity in vps35D but not WT cells
(i.e., similar to the effects of TIF4631 upregulation). Out of 5,500
genes tested, we only found 25 that caused specific growth de-
fects when upregulated in vps35D cells (Table S2). If vps35D
were simply a sick strain and/or sensitive to many different per-
turbations, wewould expect to uncover many genes. In contrast,
we find a very small number of genes as hits in this screen,
including TIF4631, the EIF4G1 homolog. Importantly, we did
not identify any other yeast translation initiation factors in this
screen, suggesting that the effects are specific to TIF4631.
Because there are many reasons why some genes might
be missed in a large screen and to further test specificity, we
directly tested four other yeast translation initiation factors,
including TIF4632, and only TIF4631 upregulation was toxic
in vps35D cells (Figure S2A). Finally, we tested specific muta-
tions in Tif4631 that interfere with its association with eIF4E
(L459,460A) or eIF4A (W579A) and therefore impair its function
in translation initiation (Park et al., 2011; Schu¨tz et al., 2008).
These were less toxic in vps35D cells than WT Tif4631 (Fig-
ure S2B). Thus, the effect on vps35D cells seems to be specific
to EIF4G1 and its function in translation initiation.
Vps35 is a component of the retromer complex (Figure 1C),
which consists of a well-conserved cargo recognition trimer,
comprised of Vps26, Vps29, and Vps35, as well as a trimer
recruitment dimer. The trimer recruitment dimer, comprised of
Vps5 and Vps17 in yeast, has multiple orthologs in mammalian
cells known as sorting nexins (Seaman et al., 1998). Deficiencies
in other retromer subunits (vps26D and vps17D) also conferredNeuron 85, 76–87, January 7, 2015 ª2015 Elsevier Inc. 77
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Figure 1. Genetic Interaction between
VPS35 and EIF4G1 in Yeast
(A) Yeast-spotting assays showing that TIF4631
upregulation (under control of a galactose-induc-
ible promoter) is toxic in cells harboring a VPS35
deletion (vps35D); 5-fold serial dilution of yeast
cells spotted onto glucose (TIF4631 ‘‘off’’) or
galactose (TIF4631 ‘‘on’’).
(B) Yeast-spotting assays demonstrating both
yeast (TIF4631) and human (EIF4G1) translation
initiation factor upregulation is toxic in vps35D
cells. Toxicity is suppressed by coexpression of
either human or yeast VPS35.
(C) A schematic showing the yeast retromer
complex comprised of a cargo recognition trimer
(Vps35, Vps26, and Vps29) and a trimer recruit-
ment dimer (Vps5 and Vps17).
(D) Genetic interactions between translation initi-
ation factor and other components of the retromer
complex. Overexpression of TIF4631 is toxic in
cells lacking several components of the retromer
complex (Vps26 and Vps17).
(E) The PD-linked VPS35 mutation, D620N, im-
pairs the ability of VPS35 to rescue toxicity from
EIF4G1 upregulation in vps35D cells. See also
Figures S1 and S2.sensitivity to TIF4631 upregulation (Figure 1D). Because PD-
linked mutations and a genetic deletion of VPS35 may behave
differently, we also tested the effects of expression of mutant
VPS35 in this assay. Whereas expression of WT human VPS35
rescued toxicity from EIF4G1 upregulation in vps35D cells,
expression of the PD-linked D620 VPS35 mutation failed to
rescue toxicity (Figure 1E). This result is consistent with the
disease-causing mutation in VPS35 impairing its function.
Thus, two seemingly unrelated PD genes, VPS35 and EIF4G1,
are able to interact in a powerful way and, in a broader sense,
retromer deficiency sensitizes cells to effects of altering transla-
tion initiation factor function.
To extend our studies from yeast and to validate the VPS35-
EIF4G1 genetic interaction in the nervous system, we used the
nematode C. elegans. The C. elegans cholinergic motor neuron
DA9 is an established system to study synapse formation in vivo
(Ou et al., 2010). The DA9 axon forms approximately 25 en
passant presynapses within a discrete and stereotyped location
along its axon, which can be visualized by GFP-tagged synaptic
vesicle proteins such as RAB-3 (Figures 2A and 2B). vps-35
single loss-of-function mutants have very subtle effects on the78 Neuron 85, 76–87, January 7, 2015 ª2015 Elsevier Inc.density and size of RAB-3 puncta (Fig-
ures 2D, 2G, and 2H), providing a sensi-
tized genetic background within which
an enhancement in synapse formation
defects can be readily visualized. In this
sensitized background, overexpression
of human EIF4G1 in the DA9 resulted in
significantly reduced number of RAB-3
puncta and dramatic increases in the
puncta size (Figures 2E, 2G, and 2H).
Overexpression of human EIF4G1 in theDA9 neurons of wild-type nematodes did not lead to obvious
synaptic phenotypes (Figures 2C, 2G, and 2H). These results
demonstrate a synthetic effect between the vps-35 mutation
and overexpression of EIF4G1 in neurons and indicate that the
VPS35-EIF4G1 genetic interaction that we discovered in yeast
is conserved and functional in the nervous system.
We next investigated the mechanistic basis for the potent
genetic interaction between VPS35 and EIF4G1. In other words,
why would vps35D and retromer deficiency sensitize cells
to translation initiation factor upregulation? Since EIF4G1 is a
scaffold protein for the assembly of a multisubunit translation
initiation complex (Villa et al., 2013), its upregulation might cause
stoichiometric imbalances leading to defects in translation lead-
ing to an accumulation of misfolded and unfolded proteins.
Impairments in retromer function would potentially impede the
cell’s ability to effectively handle these misfolded proteins. To
test this hypothesis, we used Hsp104-GFP as a misfolded pro-
tein sensor. Hsp104 is a protein disaggregase (Shorter, 2008),
diffusely localized throughout the cytoplasm and nucleus under
normal conditions but accumulates at sites of protein misfolding
and aggregation. The appearance of Hsp104-GFP foci indicates
Figure 2. EIF4G1, vps-35, and a-Syn Genetic Interactions in C. elegans Neurons
(A) A schematic showing the morphology and synaptic pattern of the C. elegans DA9 neuron. A, anterior; D, dorsal.
(B–E) Confocal images of the pattern of synaptic vesicle associated protein GFP::RAB-3 in wild-type (B), wyEx6554 (Pitr-1::EIF4G1) (C), vps-35 mutant (D), and
vps-35, wyEx6554 (E).
(F and G) Quantifications of the RAB-3 puncta density (F) and the average puncta size (G). n = 10–15 worms in each genotype. *p < 0.05; ***p < 0.001. One-way
ANOVA. Mutant a-syn (A53T) enhances the effects of vps-35 in synapse formation in DA9 neurons.
(H–K) Confocal images of SV-associated protein GFP::RAB-3 pattern in wild-type (H), wyEx5613 (Pitr-1::a-syn(A53T)mCherry) (I), vps-35 (J), and vps-35,
wyEx6513 (K).
(L and M) Quantifications of the RAB-3 puncta density (L) and the average puncta size (M). n = 10–15 worms in each genotype. **p < 0.01; ***p < 0.001. One-way
ANOVA. Scale bar, 10 mm. Error bars represent SEM.that cells are under proteotoxic stress (Oromendia et al., 2012).
In WT cells, vps35D cells, or cells with TIF4631 upregulated,
Hsp104-GFP was diffusely localized throughout the cell with
only occasional cells harboring one or two Hsp104-GFP foci
(Figure 3A), consistent with the cell’s normal ability to cope
with the consequences of translation initiation factor upregula-
tion. In contrast, in vps35D cells, TIF4631 upregulation resulted
in a dramatic increase in the percentage of cells with Hsp104-
GFP foci and in the number of foci per cell (Figure 3A). Restoring
VPS35 function to vps35D cells was sufficient to reduce the
number of Hsp104-GFP foci caused by TIF4631 upregulation
(Figure 3A). Thus, retromer deficiency, in situations when
EIF4G1 is upregulated, leads to the accumulation of protein
aggregates, which could be due to problems in protein folding
and/or impairments in the ability to effectively handle or clear
protein aggregates.
Because vps35D cells accumulated misfolded proteins upon
TIF4631 upregulation, and since the endoplasmic reticulum
(ER) is required for the proper folding of most secreted andmem-
brane proteins in eukaryotic cells, we next asked whether de-
fects in folding of these proteins causes ER stress. To combatprotein misfolding, cells activate the unfolded protein response
(UPR), a cellular program to boost protein folding, promote the
degradation of misfolded proteins, and attenuate protein trans-
lation (Walter and Ron, 2011). We used two independent ap-
proaches to test whether TIF4631 upregulation in vps35D cells
activated the UPR. First, we used a LacZ reporter fused to
unfolded protein response elements (UPREs) (Patil and Walter,
2001). Expression of TIF4631 in vps35D caused a 3-fold increase
in ER stress relative to control cells (Figure 3C). Next, we upregu-
lated TIF4631 in hac1D or ire1D cells. Hac1 and Ire1 are critical
mediators of the UPR. Upregulation of TIF4631 or EIF4G1 in-
hibited growth in hac1D or ire1D cells (Figure 3B), indicating
that a functional UPR is required to deal with misfolded proteins
that accumulate in vps35D cells expressing TIF4631 or EIF4G1.
Taken together, these data demonstrate that Vps35 and
retromer are able to mitigate the deleterious effects of protein
misfolding caused by TIF4631/EIF4G1.
Another way that misfolded proteins are normally processed
is by the sortilin family of proteins, which includes the yeast
sortilin homolog Vps10 (Dennes et al., 2002). Vps10 helps sort
misfolded proteins from the trans-Golgi network (TGN) toNeuron 85, 76–87, January 7, 2015 ª2015 Elsevier Inc. 79
Figure 3. Vps35 and the Retromer Complex Protect against Accumulation of Misfolded Proteins and Activation of UPR via Vps10/sortilin
(A) Localization of the misfolded protein sensor Hsp104-GFP in indicated yeast strains. Hsp104-GFP is distributed in a mostly diffuse pattern in WT or vps35D
cells and in WT cells overexpressing TIF4631. However, abundant Hsp104-GFP foci form as a result of overexpression of TIF4631 vps35D cells, indicating the
presence of unfolded or misfolded proteins. Restoring Vps35 function to these cells is sufficient to reduce Hsp104-GFP foci.
(B) Yeast-spotting assays showing that deletion of mediators of the UPR, IRE1 and HAC1, impair the cellular response to upregulation of TIF4631. TIF4631
upregulation is toxic in ire1D and hac1D yeast cells.
(C) Upregulation of TIF4631 in vps35D cells leads to a 3-fold increase in the activation of the UPR, measured using a LacZ reporter construct under control of the
UPR element (UPRE).
(D and E) VPS10 functions downstream of VPS35 to mediate protection against TIF4631 upregulation. (D) Upregulation of galactose-inducible yeast or human
translation initiation factors (TIF4631 or EIF4G1) is toxic in vps10D yeast cells. (E) Coexpression of VPS10 is able to fully rescue the toxicity of TIF4631 upregulation
in vps35D cells. Error bars represent SEM. See also Figures S3.prevacuolar endosomes for degradation (Reitz, 2012). Vps35
and the retromer complex help recycle Vps10 back from endo-
somes to the TGN where it can continue its surveillance for
misfolded proteins and, if necessary, initiate further rounds of
protein sorting (Seaman et al., 1997). Indeed, Vps35 was origi-
nally discovered in yeast based on its role in endosome-to-Golgi
retrieval of Vps10 (Seaman et al., 1997). We next tested whether
the protective effects of Vps35 in dealing with misfolded proteins
were mediated by Vps10. In other words, we hypothesized that
Vps10 could facilitate the sorting of misfolded proteins toward
the vacuole for degradation and Vps35 would help to retrieve
Vps10 to the Golgi for further rounds of protein quality control.
Consistent with this hypothesis, upregulation of yeast TIF4631
or human EIF4G1 was toxic in yeast cells lacking VPS10 (Fig-
ure 3D). Remarkably, overexpression of VPS10 was able to fully
suppress the toxicity associated with TIF4631 upregulation in80 Neuron 85, 76–87, January 7, 2015 ª2015 Elsevier Inc.vps35D cells (Figure 3E). These results strongly suggest that
Vps10/sortilin acts downstreamor in parallel to Vps35 tomediate
protection against TIF4631. Emerging roles for sortilin proteins
in other neurodegenerative diseases, such as FTLD and Alz-
heimer’s disease (Lane et al., 2012; Reitz et al., 2013) and our
results linking sortilin to Vps35 and PD now warrant further
examination of a role for sortilin proteins in PD. Our data are
consistent with the hypothesis that Tif4631 upregulation causes
alterations in translation in the absence of Vps35, which could
lead to protein misfolding and impairments in sortilin to cope
with these misfolded proteins. See Supplemental Information
and Figure S3, where we test this hypothesis by measuring
protein synthesis directly with polysome-profiling and ribo-
some-profiling experiments.
Given the strong interactions between two PD genes, VPS35
and EIF4G1, in both yeast cells and C. elegans neurons, we
Figure 4. Genetic Interaction between
a-Syn, VPS35, and EIF4G1 in Yeast
(A) a-Syn toxicity is enhanced in yeast cells lacking
VPS35.
(B) a-Syn-YFP subcellular localization is also
altered in vps35D cells compared to its localization
in WT cells.
(C) Upregulation of galactose-inducible yeast or
human translation initiation factors (TIF4631 or
EIF4G1) is sufficient to suppress a-syn toxicity. A
PD-linked EIF4G1 variant (R1205H) is impaired in
its ability to suppress a-syn toxicity in this yeast
assay.next investigated whether these genes might also interact with
a-synuclein (a-syn). Point mutations or multiplications in the
a-syn gene are a cause of some rare forms of PD and a-syn is
the major component of Lewy bodies, the hallmark pathological
lesion in PD (Lee and Trojanowski, 2006). To test for interactions
between a-syn and EIF4G1 or VPS35, we used the yeast a-syn
model. Numerous studies have shown that expression of a-syn
is toxic in yeast cells in a dose-dependent manner (Outeiro and
Lindquist, 2003). Deletion of yeast VPS35 enhanced a-syn
toxicity whereas the deletion of TIF4631 did not (Figure 4A).
The lack of toxicity enhancement in tif4631D could be due to
the ability of the related gene TIF4632 to compensate for loss
of TIF4631 (Clarkson et al., 2010). Compared to its normal local-
ization on the plasma membrane with occasional localization to
cytoplasmic vesicular inclusions in WT cells, a-syn formed more
numerous cytoplasmic inclusions in vps35D cells and also
frequently accumulated in the vacuole (Figure 4B). Even though
deletion of TIF4631 did not enhance a-syn toxicity, upregulation
of TIF4631 or human EIF4G1 suppressed toxicity (Yeger-Lotem
et al., 2009; Figure 4C). Interestingly, the PD-associated EIF4G1-
variant R1205H was impaired in its ability to suppress a-syn
toxicity (Figure 4C). EIF4G1 is still somewhat controversial as a
bona fide PD gene (Blanckenberg et al., 2014; Lesage et al.,
2012; Nishioka et al., 2014; Siitonen et al., 2013; Sudhaman
et al., 2013; Tucci et al., 2012). Our results functionally connect-
ing EIF4G1 to two other PD genes (VPS35 and a-syn) and the
reduced ability of a PD-associated EIF4G1 variant to suppress
a-syn toxicity in yeast, provides support for a role of EIF4G1 in
PD. Nevertheless, further sequencing of EIF4G1 in additional
PD patients and control subjects will be required to resolve the
extent to which EIF4G1 mutations cause PD.
We next sought to validate the genetic interaction between
a-syn and VPS35 in neurons and we again used C. elegans (Fig-
ures 2H–2M). Similar to the findings in yeast, overexpression of
mutant a-syn (A53T) in DA9 in the vps-35 mutants dramaticallyNeuron 85, 76–decreased the RAB-3 puncta density
and increased the puncta size (Figures
2K–2M), whereas a-syn (A53T) alone did
not affect the DA9 synapse pattern (Fig-
ures 2I, 2L, and 2M). The effects of wild-
type a-syn in the vps-35 mutant back-
ground were less severe than the A53T
mutant (Figures 2L and 2M). These resultsconfirm that the genetic interaction between VPS35 and a-syn
that we identified in yeast functions in a similar way in the ner-
vous system.
We next determined whether VPS35 could functionally impact
neurodegeneration mediated by a-syn and whether PD-linked
VPS35mutations compromise this function. We analyzed neuro-
degeneration in an established transgenic (tg) mouse synuclein-
opathy model (Masliah et al., 2000; Rockenstein et al., 2002; see
Supplemental Information for further characterization of VPS35
and EIF4G1 protein levels and localization in mouse and human
brain). Compared to non-tg controls, in a-syn tg mice, we found
reduced NeuN-positive cells in the CA3 region of the hippocam-
pus (Figures 5A and 5B). We bilaterally injected brains of a-syn tg
mice with lentiviral constructs that either upregulated human
VPS35 (WT or a PD-linked P316S mutant [Vilarin˜o-Gu¨ell et al.,
2011]) or inhibited endogenous VPS35 by shRNA-mediated
knockdown. Strikingly, upregulation of WT VPS35 was able to
almost completely rescue the a-syn-induced neurodegeneration
(Figures 5A and 5B). In contrast, upregulation of the PD-linked
mutant (VPS35 P316S) or knockdown of endogenous VPS35 re-
sulted in more marked neuronal loss in the hippocampus of the
a-syn tg mice (Figures 5A and 5B). We obtained similar results
with another PD-linked VPS35 mutant (D620N; data not shown).
Upregulation of WT VPS35 also markedly reduced neuroinflam-
mation in a-syn tg mice. Upregulation of WT VPS35 reduced
GFAP immunoreactivity to levels comparable to non-tg sections
(Figures 5C and 5D). However, VPS35 P316S upregulation
caused a significant increase in GFAP immunoreactivity (Figures
5C and 5D). These data indicate that VPS35 is able to function-
ally antagonize a-syn-mediated neurodegeneration and extend
our findings from yeast and worms to mouse.
We investigated the mechanism by which VPS35 protected
against neurodegeneration in a-syn tg mice. Because a-syn pro-
tein levels are closely linked to PD (multiplication of the SNCA lo-
cus causes early onset PD [Singleton et al., 2003] and common87, January 7, 2015 ª2015 Elsevier Inc. 81
Figure 5. VPS35 Increased Levels Are Neuroprotective against a-Synuclein-Mediated Neuronal Loss and Astrogliosis
Protein immunoreactivity in hippocampus of non-tg vehicle mice (Non-tg, LV-control) and a-syn tg mice injected with vehicle (LV-control), lentivirus VPS35 WT
(LV-VPS35 WT), VPS35 mutant (LV-P316S), and silenced VPS35 (shVPS35) has been analyzed.
(A and B) NeuN immunostaining to evaluate the neuronal loss in hippocampus of non-tg vehicle mice and a-syn tg mice overexpressing VPS35WT, mutant, VPS
silencing, and relative signal quantification.
(C and D) GFAP immunostaining to evaluate astrogliosis in hippocampus of non-tg vehicle mice and a-syn tg mice overexpressing VPS35 WT, mutant, VPS
silencing, and relative signal quantification.
(E and F) a-syn immunostaining in hippocampus of non-tg vehiclemice and a-syn tgmice overexpressing VPS35WT,mutant, VPS35 silencing, and relative signal
quantification. Error bars represent SEM. See also Figures S4–S7.variants near the SNCA locus are associated with sporadic PD
[Lill et al., 2012]), we tested the hypothesis that VPS35 upregula-
tion protects against a-syn accumulation. Upregulation of WT
VPS35 reduced the intraneuronal accumulation of a-syn in tg
mice to levels comparable to non-tg mice (Figures 5E and 5F),
whereas upregulation of VPS35 P316S or VPS35 silencing using
shRNA further increased the accumulation of a-syn (Figures
5E and 5F). These findings suggest that VPS35 functions,
at least in part, to suppress a-syn accumulation, while knock-
down or expression of PD-linked mutant VPS35 displays defec-
tive a-syn clearance resulting in widespread accumulation.
Together, these results suggest that increased levels of VPS35
are neuroprotective against a-syn-mediated toxicity. VPS35
controls a-syn accumulation in neurons and protects brain tis-
sues against neuronal loss and astrogliosis.82 Neuron 85, 76–87, January 7, 2015 ª2015 Elsevier Inc.We also tested VPS35 in another synucleinopathy model.
Emerging evidence indicates that pathological forms of a-syn
can spread from neuron to neuron in a prion-like manner (Luk
et al., 2012) and there is evidence that exogenous a-syn may
utilize endosomal transport as part of the cell-to-cell spreading
process (Volpicelli-Daley et al., 2011). Given the role of VPS35
and retromer in endosomal trafficking (Burd and Cullen, 2014),
we studied the effect of VPS35 modulation on the uptake of
exogenous a-syn fibrils into rodent cortical neurons. We infected
cortical neurons after 7 days in vitro (7DIV) for 5 days with lenti-
viruses encodingWT VPS35 or two VPS35 mutations genetically
linked in humans to PD (P316S and D620N). We also lowered
VPS35 levels with siRNA. Subsequently, neurons were exposed
to 1 mMof exogenous human recombinant a-syn seeds (see Fig-
ure S6 for detailed characterization of the recombinant a-syn
seeds) for 24 hr. We found that intracellular levels of exogenous
a-syn seeds were significantly decreased in cortical neurons
transduced with WT VPS35-expressing lentivirus compared to
the control infected neurons (Figure S7). Expressing the two
PD-linked VPS35 mutants or lowering VPS35 levels with siRNA
had the opposite effect (Figure S7). These data suggest that
endosomal dysfunction caused by defects in VPS35 and the ret-
romer complex impair the ability of neurons to cope with the
accumulation of a-syn seeds, which could hasten the prion-
like spread of PD pathology. It also suggests the possibility
that approaches to boost retromer function might help to miti-
gate a-syn accumulation and propagation. Indeed a small mole-
cule stabilizer of the retromer complex decreases pathogenic
processing of amyloid precursor protein in Alzheimer’s disease
(Mecozzi et al., 2014).
DISCUSSION
Using two genome-wide screens in yeast combined with mech-
anistic studies in yeast and functional validation in an animal
model, we provide evidence that two distinct PD risk genes,
VPS35 and EIF4G1, interact genetically and functionally. We
connect these two genes to a cellular pathway involved in the
surveillance and processing of misfolded proteins and show
how impairments in this pathway result in the accumulation of
proteinmisfolding and proteotoxic stress and how this can exac-
erbate the effects of a-syn accumulation. We provide evidence
that VPS35 can protect against neurodegeneration and a-syn
accumulation in transgenic mice and in a primary neuron a-syn
prion-like seeding model.
The toxicity caused by translation initiation factor upregulation
in the absence of a functional retromer complex can be a result
of altered translational landscape in the cell. Because EIF4G1
is a scaffold protein on which translation initiation complexes
assemble, alterations in complex stoichiometry could result in
increased or decreased translation or even alterations in the pro-
file of mRNAs translated. Such alterations in translation would
result in numerous defects in protein targeting, sorting, and
folding, which are revealed when protein quality control machin-
ery is compromised (e.g., retromer or sortilin deficiency, defects
in UPR machinery, or even decline of proteostasis machinery
with aging [Clarkson et al., 2010]). Future studies will be aimed
at quantitatively defining the contribution of alterations in trans-
lation per se to neurodegenerative disease phenotypes.
We also demonstrate that a sortilin protein acts downstreamof
Vps35 tomediate the protection against translation initiation fac-
tor upregulation. SORT1, the human ortholog of yeast VPS10,
is associated with other neurodegenerative diseases, including
Alzheimer’s disease and frontotemporal dementia (Hu et al.,
2010; Lewis and Golde, 2010), and our studies now suggest a
potential role for this gene in PD pathogenesis. Beyond sortilin,
we propose that the human homologs of the other genes from
the vps35D and tif4631D screens may help to suggest novel PD
susceptibility genes. Indeed, one of the strongest hits from the
tif4631D screen, INP53, is the yeast homolog of human SYNJ1,
which was recently linked to parkinsonism (Krebs et al., 2013;
Quadri et al., 2013). Thus, in a way, the screen has already
worked, producing another PD susceptibility gene, and it nowwarrants closer examination of the other hits from the yeast
screens (Table S1) for connections to PD in humans. Large-scale
exome sequencing projects are underway (Novarino et al., 2014)
and promise to expand and clarify the genetic landscape of
neurodegenerative diseases, including PD (Bonifati, 2014). Novel
functional approaches to assess biological functions of candi-
date disease genes and risk factors will hopefully aid in the inter-
pretation and analysis of the human sequencing data.
The functional links between Vps35 and a-synuclein reported
here in yeast, worms, and mouse underscore a role of perturba-
tions in vesicle trafficking pathways as a component of PD path-
ogenesis (Cooper et al., 2006;Gitler, 2008;MacLeod et al., 2013).
The unexpected link between translation initiation factor eIF4G1
and Vps35, including the role of protein misfolding and activation
of the unfolded protein response, illuminates translation regula-
tion and protein quality control pathways aswell. Proteinmisfold-
ing and impairments in protein degradation lie at the heart of
neurodegenerative diseases, including PD (Forman et al., 2004).
These results are also strikingly consistent with a recent report
of alterations in translational control mediating neurodegenera-
tion in PD caused by LRRK2 mutations (Martin et al., 2014).
Our findings that the retromer complex can normally combat
the accumulation of unfolded and misfolded proteins, masking
the toxic effects of alterations in levels of translation initiation fac-
tor expression, helps to explain how mutations in Vps35 could
lead to PD and how other genetic or environmental susceptibil-
ities that might lead to misregulated translation could also result
in neurodegeneration (Lee and Trojanowski, 2006). Because
expression of Vps35 or sortilin proteins can suppress the toxicity
associated with EIF4G1 upregulation, screening for compounds
that boost retromer or sortilin levels or function could be an
effective therapeutic strategy. The yeast models presented
here should provide a tractable system for such screens.
EXPERIMENTAL PROCEDURES
Yeast Experiments
We generated the vps35D and tif4631D query strains by replacing the VPS35
and TIF4631 coding region with the natMX resistance cassette in strain Y7092;
MATa can1D::STE2pr-Sp_his5 lyp1D his3D1 leu2D0 ura3D0met15D0. Strains
were manipulated and media prepared using standard techniques. We ob-
tained the yeast VPS35 and TIF4631 entry clone constructs from the Yeast
FLEXGene library (Harvard Institute of Proteomics). For the UPRE-LacZ
b-galactosidase activity assays, yeast strains were grown to mid-log phase,
induced with 2% galactose (or repressed with 2% glucose) for 4 hr, and
then lysed with Y-PER Plus Extraction Reagent (Thermo, 78999) with 13
Halt Protease Inhibitor Cocktail. Afterward, protocol was followed as per the
Yeast b-Galactosidase Activity Kit (Thermo, 75768).
vps35D and tif4631D Synthetic Lethality Screens
We used synthetic genetic array (SGA) analysis to identify nonessential yeast
deletions that are synthetic lethal with vps35D or tif4631D. We performed this
screen essentially as described in (Tong and Boone, 2006), with some modifi-
cations, using a Singer RoToR HDA (Singer Instruments). We mated the MATa
vps35D or tif4631D query strain to the yeast haploid deletion collection of
nonessential genes (MATa, each gene deleted with KanMX cassette confers
resistance to G418). Following diploid selection and sporulation, we selected
double mutant haploids. Colony sizes were measured using the ht-colony-
measurer software (Collins et al., 2006). The raw values were normalized
by dividing them by the median colony size of the plate. We performed the
entire screen three independent times. The data from three rounds were aver-
aged and the difference between double and single mutant colony size wasNeuron 85, 76–87, January 7, 2015 ª2015 Elsevier Inc. 83
calculated and used to call a synthetic sick/lethal interaction. We used
GOTermFinder to identify significant gene ontology (GO) terms enriched as
hits in each screen. A description of how p values are calculated is presented
in Boyle et al. (2004).
Worm Experiments
Worms were raised on NGM plates at 20C, using OP50 E.coli as a food
source. N2 Bristol was used as the wild-type reference strain. The following
mutant strains were obtained through the Caenorhabditics Genetics Center:
KN555 vps-35(hu68) II. Expression clones were made in the pSM vector, a
derivative of pPD49.26 (A kind gift from A. Fire) with extra cloning sites. The
wyIs85 integrated worm strain was described as previously (Klassen and
Shen, 2014). The transgenic strains were generated as the following:
wyEx6554 (Pitr-1::EIF4G1): the human EIF4G1 cDNA was amplified from
Gateway entry clone vector containing full-length cDNA of EIF4G1 and subcl-
oned into the Pmig-13 DpSM between the AscI and EcoRV sites. The Pmig-13
promoter was then replaced by Pitr-1 promoter between SphI and AscI sites.
The plasmid was then injected into vps-35;wyIs85 at 4.0 ng ml1, with 40 ng
ml1 Podr-1::GFP. Two extrachromosomal arrays were generated, and all
showed similar effects. wyEx5609 (Pitr-1::a-synuclein::mcherry), wyEx5609
(Pitr-1:: a-synucleinA53T::mcherry): the human a-synuclein wild-type and
A53T cDNA were subcloned from pDONR-a-syn and pDONR-a-synA53T,
respectively, into worm expression vector Pitr-1::mcherry DpSM. The plas-
mids were injected into wyIs85 at 50 ng ml1, with 40 ng ml1 Podr-1::GFP. Im-
ages of fluorescently tagged fusion proteins were captured in live C. elegans
using a plan-Apchromat 40X1.3 objective on a Zeiss LSM710 confocal micro-
scope, using identical image and laser setting for each genotype. Young adult
hermaphrodites were immobilized using 3 mM levamisole (sigma) dissolved in
M9 buffer. Straightened DA9 dorsal cords were extracted from the confocal
images using the ‘‘straighten to line’’ in the ‘‘ROI’’ plug-in program of ImageJ,
then aligned along the anteroposterior axis using the DA9 commisure turning
point as a reference mark. The puncta number and size were calculated using
the ‘‘analyze particles’’ program of Image J.
Transgenic Mouse Lines and Injections of Lentiviral Vectors
For this study, mice overexpressing a-synuclein from the Thy1 promoter (Line
61) were utilized (Rockenstein et al., 2002). This model was selected because
mice from this line develop intraneuronal a-synuclein aggregates distributed
through the brain including the thalamus and substantia nigra similar to what
has been described in LBD. A cohort of n = 10 non-tg and 40 tg (LV-control,
LV-VPS35 wt, LV-VPS35 P316S, LV-shVPS35, n = 10mice per group) were in-
jected with 3 ml of the lentiviral preparations (2.53 107 TU) into the hippocam-
pus (using a 5 ml Hamilton syringe). Briefly, mice were placed under anesthesia
on a Koft stereotaxic apparatus and coordinates (hippocampus: AP 2.0 mm,
lateral 1.5 mm, depth 1.3 mm) were determined as per the Franklin and
Paxinos atlas. The lentiviral vectors were delivered using a Hamilton syringe
connected to a hydraulic system to inject the solution at a rate of 1 ml every
2 min. To allow diffusion of the solution into the brain tissue, the needle was
left for an additional 5 min after the completion of the injection. Mice survived
for 3 months after the lentiviral injection. Brains and peripheral tissues were
removed and divided sagitally. The right hemibrain was post-fixed in
phosphate-buffered 4% PFA (pH 7.4) at 4C for 48 hr for neuropathological
analysis, while the left hemibrain was snap-frozen and stored at 70C for
subsequent protein analysis.
Immunohistochemical and Image Analysis
Analysis was performed using free-floating, 40-mm-thick, vibratome, blind-
coded sections, as previously described (Games et al., 2013). Briefly, sections
were incubated overnight at 4C with antibodies against total a-syn (1:500,
affinity purified rabbit polyclonal, Millipore) (Masliah et al., 2000), mousemono-
clonal a-syn (clone SYN211 Life Technologies, 1:300), and VPS35 (1:500;Milli-
pore), followed by biotin-tagged anti-rabbit or anti-mouse IgG1 (1:100, Vector
Laboratories) secondary antibodies, Avidin D-HRP (1:200, ABC Elite, Vector),
and visualized with diaminobenzidine (DAB). Sections were scanned with a
digital Olympus bright field digital microscope (BX41). Analysis of neurodegen-
erative pathology was performed in vibratome sections immunolabeled with
antibodies against the panneuronal marker NeuN (1:500, Millipore) and the as-84 Neuron 85, 76–87, January 7, 2015 ª2015 Elsevier Inc.troglial marker glial fibrillary acidic protein (GFAP, 1:1000, Millipore) (Games
et al., 2013; Masliah et al., 2000). Sections reacted with biotinylated secondary
antibodies, Avidin D-HRP, and visualized with DAB. GFAPwas analyzed with a
digital Olympus bright field digital microscope (BX41). For each case, a total of
three sections (four digital images per section at 4003magnification) were ob-
tained from the CA1 and CA3 region of the hippocampus and analyzed as pre-
viously described with the Image J program (NIH) to obtain optical density;
levels were corrected to background. Sections labeled with Iba-1 were
analyzed utilizing the Image-Pro Plus program (Media Cybernetics) (ten digital
images per section at 4003 magnification) and analyzed in order to estimate
the average number of immunolabeled cells per unit area (mm2) and the
average intensity of the immunostaining (corrected optical density). Additional
analysis of a-syn was performed in vibratome sections immunolabeled with
the SYN211 monoclonal antibodies and visualized with FITC and laser-scan-
ning confocal microscopy as previously described (Games et al., 2013).
The numbers of NeuN-immunoreactive neurons were estimated utilizing
unbiased stereological methods (Overk et al., 2009). Hemi-sections containing
the neocortex, hippocampus, and striatum were outlined using an Olympus
BX51 microscope running StereoInvestigator 8.21.1 software (Micro-
BrightField). Grid sizes for the hippocampal CA3 and CA1 pyramidal layers
were 300 3 300 mm and the counting frames were and 50 3 50 mm, respec-
tively. The average coefficient of error for each region was 0.9. Sections
were analyzed using a 100 3 1.4 PlanApo oil-immersion objective. A 5 mm
high dissector allowed for 2 mm top and bottom guard zones.
Preparation and Treatment of Mouse Primary Cortical Neurons
Primary cortical neuronal cultures were prepared from the neocortices of
1-day-old mice (P1) as previously described (Hirling et al., 2000). Cortical
hemispheres were isolated in Hank’s balanced salt solution (HBSS, Invitrogen)
and incubated in 0.1% papain (Sigma-Aldrich). After 10 min, the papain was
removed, and the reaction was blocked using 30% fetal calf serum (FCS,
Invitrogen). Individual cells were obtained by trituration (83) and then the
cells were resuspended in MEM medium 13 (Invitrogen) supplemented with
0.5 mM L-glutamine 200 mM (Invitrogen), 5% heat-inactivated fetal calf serum
(FCS, Invitrogen), and 2% penicilin/streptomycin (Pen/Strep, Invitrogen) for
4 hr. Cells were seeded at density of 3.5 3 105 cells on 35 mm dish and in
12-well plates a density of 1 3105 with miscrope cover glass (Fisherbrand)
both previously treated with 0.01% poly-L-Lysine (Sigma) for 1 hr. After 4 hr
the media was removed and changed with NeuroBasal (NB) medium (Invito-
gen) supplemented with 13 B27 (Invitrogen), 0.5 mM glutamine, and 2%
Pen/Strep. After 10DIV, the differentiated cortical neurons were treated
following the experimental procedures.
Lentivirus Infection and Gene Silencing
The VPS35WT and mutants cDNA was PCR amplified and cloned into the len-
tivector to generate LV-VPS35wt, P316S, and D620N as previously described
(Spencer et al., 2009) to generate LV-shVPS35. The control shRNA lentivector
(LV-shLuc) contains an shRNA directed against firefly luciferase. The lentivirus
vector expressing the human wild-type a-syn has been previously described
(Bar-On et al., 2008). Lentiviruses were prepared by transient transfection in
293T cells. VPS35 gene was silenced by transfection with siRNA VPS35
(Silencer Select, Ambion, Life Technologies). The siRNA VPS35 was coincu-
bated with Lipofectamine RNAiMAX reagent (Invitrogen) and then added at
the cells. Lipofectamine and siRNAwere added at the cells cultured inmedium
without serum and antibiotic for 5 hr and then shifted back with complete me-
dium for siRNA negative control (Silencer Select, Ambion, Life Technologies).
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